Last reviewed · How we verify
sintilimab plus platinum-based chemotherapy
At a glance
| Generic name | sintilimab plus platinum-based chemotherapy |
|---|---|
| Also known as | Group A, Group B, Group C |
| Sponsor | Tang-Du Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients (PHASE2)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC (PHASE3)
- ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs (PHASE2)
- Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery (PHASE2)
- A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (PHASE2)
- Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma (PHASE3)
- Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |